Financing ·
Inhibikase swaps 18.03M shares for pre-funded warrant with $0.001 exercise price under Securities Act exemption
IKTInhibikase Therapeutics, Inc.
On July 29, 2026, Inhibikase Therapeutics entered into an exchange agreement with RA Capital Healthcare Fund to swap 18,030,000 shares of common stock for a pre-funded warrant. The warrant carries a $0.001 exercise price, is immediately exercisable, and has no expiration date. It includes a beneficial ownership blocker limiting holdings to 9.99% of outstanding shares, adjustable with notice up to 19.99%. This transaction was executed under Section 3(a)(9) of the Securities Act exemption. Inhibikase Therapeutics operates in the biotechnology industry, focusing on drug discovery and development.